Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S 6 Dose Levels Study in Healthy Adults
NCT04908722Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Geometric Mean Concentration of SARS-CoV-2 S Protein Binding Antibodies Measured by ELISA 28 Days After First Vaccination and Geometric Mean Concentration of SARS-CoV-2 S Protein Binding Antibodies Measured by ELISA 14 Days After Second Vaccination. Started Jun 2021; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04908722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908722.